Lung Cancer Clinical Trials in Atlanta

Showing 361-380 of 755 trials

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

NCT05271292

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.

Small Cell Lung CancerAdvanced Solid Malignant Tumor

Chipscreen Biosciences, Ltd.36 participantsStarted Aug 2022

Encinitas, California, United States • Fullerton, California, United States • Atlanta, Georgia, United States +8 more locations

COMPLETEDPhase 1< 1 mile

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more

Xencor, Inc.198 participantsStarted May 2019

San Diego, California, United States • Aurora, Colorado, United States • Denver, Colorado, United States +15 more locations

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Lung Cancer Trials in Other Cities

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Other Conditions in Atlanta